Literature DB >> 24229809

Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy.

Barbara Collins1, Joyce Mackenzie1, Giorgio A Tasca1, Carole Scherling2, Andra Smith3.   

Abstract

Numerous studies have shown that there are acute cognitive side-effects of chemotherapy for breast cancer. Presumably, patients are more concerned about chronic treatment effects. This report from a prospective longitudinal study compares cognitive functioning in 56 breast cancer patients 1 year after chemotherapy to that of 56 healthy individuals. Neuropsychological test scores were combined into verbal memory, visual memory, working memory, and processing speed scores, as well as an overall summary score, and analyzed using multi-level growth modeling. Frequency of cognitive decline was assessed using regression-based change scores. There was significant rebound in the overall summary score from end of treatment to 1-year follow-up as well as a substantial reduction in the frequency of cognitive decline. However, more than one-third of the breast cancer patients who showed cognitive decline immediately following completion of chemotherapy showed persistent cognitive decline 1 year later. Furthermore, recovery was not seen in all cognitive domains. In fact, the rebound was significant only for working memory. Longer multi-site studies are recommended to explore the risk factors for and the permanence of these longer-term cognitive effects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24229809     DOI: 10.1017/S1355617713001215

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  23 in total

Review 1.  Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.

Authors:  M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel
Journal:  Ann Oncol       Date:  2019-12-01       Impact factor: 32.976

2.  Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems.

Authors:  Shannon L Gutenkunst; Janette L Vardy; Haryana M Dhillon; Melanie L Bell
Journal:  Support Care Cancer       Date:  2020-07-14       Impact factor: 3.603

3.  The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients.

Authors:  Huaidong Cheng; Wen Li; Chen Gan; Bo Zhang; Qianqian Jia; Kai Wang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

4.  Relationships among psychoneurological symptoms and levels of C-reactive protein over 2 years in women with early-stage breast cancer.

Authors:  Angela Starkweather; Debra Lynch Kelly; Leroy Thacker; Michelle L Wright; Colleen K Jackson-Cook; Debra E Lyon
Journal:  Support Care Cancer       Date:  2016-09-06       Impact factor: 3.603

5.  Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study.

Authors:  D D Correa; J C Root; M Kryza-Lacombe; M Mehta; S Karimi; M L Hensley; N Relkin
Journal:  Brain Imaging Behav       Date:  2017-12       Impact factor: 3.978

Review 6.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

7.  Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy.

Authors:  Myrle M Stouten-Kemperman; Michiel B de Ruiter; Matthan W A Caan; Willem Boogerd; Martijn J Kerst; Liesbeth Reneman; Sanne B Schagen
Journal:  Hum Brain Mapp       Date:  2015-08-25       Impact factor: 5.038

8.  The dorsolateral prefrontal cortex is selectively involved in chemotherapy-related cognitive impairment in breast cancer patients with different hormone receptor expression.

Authors:  Haijun Chen; Ke Ding; Jingjing Zhao; Herta H Chao; Chiang-Shan R Li; Huaidong Cheng
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

9.  Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations from the Cancer Neuroscience Initiative Working Group.

Authors:  Ashley M Henneghan; Kathleen Van Dyk; Tara Kaufmann; Rebecca Harrison; Christopher Gibbons; Cobi Heijnen; Shelli R Kesler
Journal:  J Natl Cancer Inst       Date:  2021-02-26       Impact factor: 13.506

10.  Elevated Oxidative Stress and DNA Damage in Cortical Neurons of Chemotherapy Patients.

Authors:  Matthew Torre; Adwitia Dey; Jared K Woods; Mel B Feany
Journal:  J Neuropathol Exp Neurol       Date:  2021-08-11       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.